Boston Scientific prices new public debt offerings, including $3.0 billion of U.S. dollar-denominated senior notes and €4.25 billion of euro-denominated senior notes, the company says. PR Newswire reports the pricing of the offerings and provides deal details from the company’s announcement.
Seeking Alpha and Investing.com both focus on the fact that Boston Scientific has priced the debt transactions, framing the news as an already-settled financing rather than a proposed sale. While their titles emphasize the pricing and the overall size of the issuance, PR Newswire includes more of the formal “announced today” context and deal-description language tied to the company’s statement.